CollPlant Biotechnologies Ltd.

Welcome to the Coal Plant Biotechnologies Investor Conference call to discuss financial results for the full year and fourth quarter of 2024 and corporate updates. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Doreen. Korowski of LifeSci Advisors. Thank you. Please go ahead.

I would like to welcome everyone to Coal Plant Biotechnology's Financial Results Conference Call to discuss the results for the full year and fourth quarter ended December 31st, 2024, where management will also provide a corporate business update. With us on the call today from Coal Plant are Yahil Tal, Chief Executive Officer of who will provide a brief overview of the company's programs and associated updates, and Iran Rotem, Deputy CEO and Chief Financial Officer, who will provide a summary of CoalClan's financial results for the full year and fourth quarter ended December 31, 2024. Both will be available to answer questions on today's call. Before we get started, I would like to remind everyone that statements made on this conference call may include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of coal plants filings with the Securities and Exchange Commission. These filings can be found at www.sec.gov or on Coal Plant's website at www.coalplant.com. In addition, any forward-looking statements made on this call represent Coal Plant's views only as of today, March 26, 2025, and should not be relied upon as representing the company's views as of any subsequent date. Coal Plant Management specifically disclaims any obligation to update or revise any of these forward-looking statements. Finally, coal plant management will refer to certain financial measures not reported in accordance with GAAP on this call. You can find reconciliations of these non-GAAP financial measures to the GAAP financial measures in the earnings press release that Coal Plant published earlier today, and which is available on Coal Plant's website at ir.coalplant.com. Now let me turn the call over to Yahil Ta, Chief Executive Officer of Coal Plant Biotechnologies. Please go ahead, sir.

Good morning, everyone, and thank you for joining us today on Cold Plants Investor Conference Call to discuss our fourth quarter and full year 2024 financial results and corporate development as we pursue our mission to be a leader in regenerative medicine. You may have seen that the field of regenerative medicine was highlighted at the end of the last year when the first lab-grown blood vessels were approved by FDA for use by surgeons to restore blood flow in patients with traumatic injuries or in patients who need coronary bypass. This approval is a major milestone for the sector, a research and development effort that has finally been able to translate from an exciting bedside idea to an actual FDA-approved product. As such, we want to emphasize our own proprietary programs in regenerative medicine and regenerative aesthetics and that we are advancing these programs ourselves through preclinical and clinical studies and ultimately potential collaborative agreements. The advancement of our Wally-owned programs represent an additional opportunity for long-term value creation for our stakeholders at Cold Plants. Therefore, I would like to start with highlighting our photocurable dermal filler candidate, which is in the preclinical phase. The photocurable dermal filler is our own, and the market it is intended for is valued approximately $6.3 billion, and with compound annual growth rate of 10%. We have received very positive feedback from talk leaders in the field of aesthetic medicine related to the experimental use of the photocurable dermal filler. Highlights from these testimonials mention that it could be a game changer for facial plastic surgery and the soft tissue filler, as well as huge advance in the dermal and soft tissue market. and for facial plastic surgery, and that nothing like this is observed with available fillers with the potential to change the overall approach of long-lasting facial sculpting. Full video testimonials from each physician can be found within our corporate presentation on our website. In addition to our proprietary photocurable dermal filler in development, our collaboration with AbbVie is focused on the development of another dermal and soft tissue filler product for the medical aesthetics market. In February 2025, Cold Plant announced that AbbVie is collecting data and conducting a review of the results from the first cohort of patients enrolled in the dermal and soft tissue filler clinical trials initiated in 2023. Next steps for the program are to be determined upon complete assessment. In addition, following a development achievement, Corplant received a $2 million payment from Avli. Now, on to our second proprietary program in regenerative medicine, our regenerative breast implants. This quarter, we continue to advance the preclinical testing of our commercial-sized breast implants, now 250 in volume. This study now, using these commercial-sized prototypes, is critical to advancing our technology towards a marketed product and creating significant shareholder value. In August 2024, Kotland launched this preclinical study with two arms, where the surgical protocol was refined to include implantation through small incision while preventing implant displacement or inversion. We were able to accomplish this with enhanced, more durable form of the implant that we were able to produce. Analysis of MRI and ultrasound data conducted early this year confirmed visual integration and vascularization, offering valuable diagnostic tools for future clinical applications. At six months post-implantation, one study arm has shown promising outcomes with the implant demonstrating vascularization and rapid tissue ingrowth within the clinical-sized implant. No complications such as capsule formation, calcifications, and local tissue reactions were observed. Additionally, volume retention and mechanical properties were maintained in the successful study arms. Following this study, Colplant will continue to optimize the regenerative breast implants to ensure longevity and remodeling of the nail tissue with the goal of readying the implants to enter the clinic. Our regenerative breast implant product candidate would be revolutionary for both women undergoing aesthetic enhancement as well as cancer patients undergoing breast reconstruction. since it has the potential to overcome the challenges of existing breast implants made of silicone, saline, or autologous fat tissue. Our recombinant human collagen technology, which is the backbone of our product candidate pipeline and commercial products, is the most characterized collagen on the market today, including its molecular, biological, and physical properties. There is continuous demand for our bioinks, and other applications for recombinant human collagen. Along these lines, we have had additional interest from a wide range of companies that want to gain access to our RH collagen and are engaged in discussions. That concludes my initial remarks. Now I will turn the call over to our Deputy CEO and Chief Financial Officer, Eran Wotem, to provide a recap of the financial results.

Thank you, Yachiel. Good morning, everyone.

I will now review our financial results for the three and 12 months period ending December 31, 2024. Gut revenues for the fourth quarter ended December 31, 2024, where $164,000 compared to $299,000 for the fourth quarter ended December 31st, 2023. The decrease we see is mainly related to sales of our Rh-collagen products. GAP revenues for the year ended December 31st, 2024 were $515,000, compared to $11 million for the year ended December 31st, 2023. In 2023, we achieved a milestone with respect to the agreement, which triggered a $10 million payment in 2023. This is the main reason for the decrease we see in revenues between these periods. That cost of revenues for Q4 2024 was $272,000 compared to $773,000 in Q4 2023. Gap cost of revenue for the year ended December 31st, 2024 was $1.6 million, compared to $2 million for the year ended December 31st, 2023. The decrease in cost of revenue is in the amount of approximately $400,000, mainly comprised of $312,000 in royalty expenses to the IAA, mainly related to the milestone payment received from AbbVie in 2023, and a decrease of $324,000 related to bioink and NIH collagen cells, offset by $247,000 related to inventory and permits. That gross loss for Q4 2024 was $108,000 compared to $474,000 in Q4 2023. GAP gross loss for the year ended December 31st, 2024 was $1.1 million compared to a gross profit of $9 million in 2023. GAP operating expenses for Q4 2024 were $3.9 million compared to $4.6 million in Q4, 2023. The decrease in operating expenses of approximately $700,000 is mainly related to a decrease of $303,000 in employees, salaries, and share-based compensation expenses, and a decrease of $386,000 in research and development activities. Gas operating expenses. for the year end of December 31st, 2024, was $16.1 million, compared to $16.5 million for the year 2023. The decrease of approximately $400,000 is mainly related to a decrease in general administrative and marketing expenses, mainly comprised of $287,000 in share-based compensation expenses,

and $152,000 in insurance policy costs.

Financial income net for Q4 2024 totaled $96,000 compared to $379,000 in Q4 2023. Financial income net for the year ended December 31, 2024 totaled $642,000 compared to $493,000 in the year ended December 31, 2023. The increase in financial income is due to exchange rate differences. Gap net loss for Q4 2024 was $3.9 million, or $0.34 basic loss per share, compared to a net loss of $4.7 million, or $0.41 basic loss per share for Q4 2023. Gap net loss for the year ended December 31, 2024, was $16.6 million, or $1.45 basic loss per share. compared to a net loss of $7 million, or $0.62 basic loss per share, for the year 2023. The main difference in performance between the periods arises from Corp's achievement in 2023 upon reaching a milestone in the dermal filler development plan, achieving the milestone, as you already know, led to a payment of $10 million, from AbbVie to Polpent in 2023. And now I will review some of the balance sheet and cash flow data. Cash and cash equivalents as of December 31st, 2024, were $11.9 million. In addition, following a development achievement under the AbbVie agreement, Polpent received a $2 million payment from AbbVie during Q1, 2025, And the cash balance represents, as of today, the company's cash runway that is expected to satisfy the company's operations requirements through the second quarter of 2026, based on currently contemplated operations and plans. Cash used in operating activities during the year ended December 31, 2024, was $14.1 million, compared to $2.8 million for the year ended December 31st, 2023. Cash used in investing activities during the year ended December 31st, 2024 was $539,000 compared to $1.2 million that was provided by investing activities for the year ended December 31st, 2023 and relating primarily to the purchase of property and equipment. Cash provided by financing activities during the year ended December 31st, 2024 was $9,000, compared to $1.1 million for the year ended December 31st, 2023. The period last year included proceeds from the exercise of the last warrants that the company granted to investors in previous years. This now concludes the financial summary. Operator, I believe that we can now open the call for questions.

Thank you. The floor is now open for questions. If you would like to ask a question, please press star 1 on your telephone keypad at this time. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. Our first question is coming from of HC Wainwright, please go ahead.

Thank you. This is RK from HC Wainwright. A couple of quick questions. So just trying to understand when would we potentially get an update from AbbVie on the studies that they are doing? And in 2025, should we expect any milestone payments?

Hi, RK. This is Iran. Thank you for joining us, and thank you for the question. So just to remind everyone, under the agreement between Cold Plant and AbbVie, AbbVie is developing a dermal filler product. And as we updated about a month ago, the dermal filler product candidate is currently in the clinical phase. And Avi is collecting data and conducting a review of interim results for the first cohort of patients enrolled under the trial initiated in 2023. The next steps for the program are to be determined by Avi upon conducting their assessment. We are not a part of the timelines here and we are following AbbVie. So whenever they will update us, of course, we will update the market. And I will mention maybe in this relation that the last month following development achievement, we received $2 million payment from AbbVie in February, which is according to the agreement. And also you remember probably that in 2023, we received another $10 million from another milestone. And the product development process is under the complete control of AbbVie. And we cannot estimate, therefore, we cannot estimate when will be another milestone.

Okay. Thank you for that. And then very recently, you know, you expanded your distribution channels for the VirginX product. in in europe and some parts of asia um what's the market there for this product and you know how how how should we think about revenue flow from this relationship um and and you know is there anything that you can um help us um estimate on on flow of payments

So first of all, this is Yechiel.

Let me explain about the product itself. The product is called Vergenix STR. STR stands for soft tissue repair. The product is basically intended for the treatment of tendinopathy, which is tendon inflammations, like, for example, tennis elbow, rotator cuff, Achilles tendon, plantar fasciitis, and others. The product is based on collagen in combination with PRP, which is autologous. It's platelets-rich plasma, which is harvested from the patient. The market for this product is sports medicine, mostly from sport injuries. In terms of the market potential, the market potential is between 1% to 3% of the population. the market potential for tendon injuries. So basically what we are trying to do now is establishing a distribution network in Europe as well as in Asia. This is in the initial stage. Each country should go through a regulatory process, so we are working on that. And hopefully after establishing this regulatory approval for the Asian countries, we should be able to start selling the product. And again, it will be a market penetration process, but we feel very comfortable about the potential because the competitor product is injection of steroids. And repeat injections of steroids is harming the tissue, the treated tissue, and it's not going to basically cure the tendinopathy issue. Our product, usually a single injection will take care about the inflammation. This is based on data that we collected from European customers. And for this reason, we feel very comfortable about the potential and hopefully we'll start to see cells in the next year.

Okay. Thank you. Thank you for taking my questions. Thank you.

Thank you. At this time, I'd like to turn the floor back over to Mr. Rotem for any web submitted questions.

Thank you. So we had a few questions coming through regarding the company's cash flow, the burn rate of the cash, the estimated cash flow. And if I'm summarizing those questions, then I can address them as follows. I mean, some of them mentioning that the company has $11.9 million at the end of the year in cash, and that we had some reduction plan to cut costs, and they're wondering about for how long it can take us, what is the bandwidth. So please note that The balance is not including the additional $2 million that the corporate received, just received from AbbVie in February. And the cost reduction that we implemented in the company, it is not impacting materially the main development programs, by the way, or the AbbVie collaboration. And the cash runway guidance that we are implementing counting on is not including any additional potential partnership revenues. So all in all, with this current cash position that we are holding and under conservative assumptions, that we are saying that this still, we will be able to continue operation into the second quarter of 2026, more than a year from now. So relatively, we are in a stable position in these shaky markets. And we are all aware to the market condition and the share price. And we see that all situation, of course, as a macro event. It's not something that happened in the company. And we have enough cash for more than a year as of today. So this is regarding a few questions that we received from the audience. So that concludes the questions from the audience, and I'll now turn the call back to Yechiel Tal, the Cold Plant Chief Executive Officer, for any closing remarks. Yechiel?

Yes, thank you, Ryan. Cold Plant continues to carefully focus on our core programs and our supportive partners to discover, develop, and provide collagen technology and regenerative medicine products to improve and prolong lives. As a result, we want to be sure that we are transparent with you, our shareholders, about our upcoming catalyst for the company for the remainder of the year related to our proprietary programs. For our photocurable dermal and soft tissue filler product candidate, our plan is to potentially launch a clinical trial within two years. For our regenerative breast implant program, we will continue to optimize the characteristics of the implant to ensure optimal regeneration of the new tissue, as well as optimize our clinical protocol with the aim to reach readiness for clinical trial. Related to our Vergenix STR marketed product, we will continue to expand the distribution network of this product in Europe and Asia. For our portfolio of novel bio-inks, we plan to broaden our product offerings to support various bioprinting technologies. And finally, related to the sales of our RH collagen as a raw product, We plan to expand sales to selected customers that comply with our business model. We will, of course, continue to focus on advancing the development of the dermal filler program with AbbVie. And we will also continue to advance any potential partnership discussions. Thank you, everyone, for your time this morning and for joining us today for today's conference call. I want to thank our very important and valued Cortland team members who have contributed to another successful and productive quarter.

Ladies and gentlemen, this concludes today's event. You may disconnect your lines and log off the webcast at this time and enjoy the rest of your day.